Stock listing
BX Swiss:12X1 Anavex Life Sciences Corp. Aktie
Swiss listing (BX Swiss) of Anavex Life Sciences Corp. · home listing NASDAQ:AVXL
Follow Anavex Life Sciences Corp. into a list and get an email when it puts out news.
Home listing price · NASDAQ:AVXL
$0.592 USD -0.128 (-17.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AVXL
- Day range
- $0.590 – $0.710 USDNov 20, 2026
- Volume
- 1.64M sharesNov 20, 2026
- Market cap
- $54.83M USDAt the close on Nov 20, 2026 · price × 92.70M shares outstanding
- 52-week range
- $0.590 – $5.360 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.97M USDMedian day 1.02M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AVXL · Home | $0.592 USD | -0.128 (-17.8%) | 1,635,526 | $0.668 | $0.710 | $0.590 | $0.719 | Close on Nov 20, 2026 |
| LSE:0HFR | $0.624 USD | -0.044 (-6.5%) | 10,821 | $0.668 | $0.704 | $0.619 | $0.667 | Close on Nov 20, 2026 |
| Frankfurt:12X1 | €0.478 EUR | -0.040 (-7.7%) | — | €0.492 | €0.492 | €0.478 | €0.517 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AVXL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.592 | -0.128 | -17.8% | $0.668 | $0.710 | $0.590 | 1,635,526 | |
| $0.719 | -0.021 | -2.8% | $0.739 | $0.780 | $0.715 | 1,056,954 | |
| $0.740 | -0.078 | -9.5% | $0.830 | $0.840 | $0.708 | 2,251,523 | |
| $0.818 | -0.116 | -12.4% | $0.940 | $0.950 | $0.800 | 2,724,279 | |
| $0.934 | -0.056 | -5.6% | $1.000 | $1.000 | $0.917 | 1,289,418 | |
| $0.989 | -0.071 | -6.7% | $1.050 | $1.055 | $0.980 | 1,249,634 | |
| $1.060 | -0.070 | -6.2% | $1.130 | $1.140 | $1.050 | 903,524 | |
| $1.130 | -0.090 | -7.4% | $1.200 | $1.230 | $1.120 | 582,761 | |
| $1.220 | +0.070 | +6.1% | $1.160 | $1.255 | $1.130 | 1,041,397 | |
| $1.150 | +0.040 | +3.6% | $1.120 | $1.150 | $1.095 | 1,053,819 | |
| $1.110 | -0.150 | -11.9% | $1.260 | $1.260 | $1.065 | 1,566,943 | |
| $1.260 | +0.060 | +5.0% | $1.240 | $1.285 | $1.220 | 927,736 | |
| $1.200 | +0.060 | +5.3% | $1.150 | $1.250 | $1.145 | 813,287 | |
| $1.140 | -0.050 | -4.2% | $1.180 | $1.200 | $1.130 | 1,110,975 | |
| $1.190 | -0.110 | -8.5% | $1.300 | $1.300 | $1.180 | 1,195,922 | |
| $1.300 | 0.000 | 0.0% | $1.310 | $1.320 | $1.270 | 898,175 | |
| $1.300 | -0.010 | -0.8% | $1.300 | $1.305 | $1.245 | 1,024,843 | |
| $1.310 | +0.030 | +2.3% | $1.260 | $1.315 | $1.250 | 1,350,722 | |
| $1.280 | -0.050 | -3.8% | $1.310 | $1.310 | $1.255 | 912,370 | |
| $1.330 | -0.030 | -2.2% | $1.340 | $1.349 | $1.290 | 626,212 | |
| $1.360 | 0.000 | 0.0% | $1.330 | $1.405 | $1.330 | 1,015,000 | |
| $1.360 | 0.000 | 0.0% | $1.400 | $1.400 | $1.310 | 1,052,500 | |
| $1.360 | +0.110 | +8.8% | $1.250 | $1.400 | $1.225 | 1,672,700 | |
| $1.250 | -0.060 | -4.6% | $1.300 | $1.310 | $1.140 | 1,873,900 | |
| $1.310 | -0.170 | -11.5% | $1.470 | $1.470 | $1.300 | 1,469,900 | |
| $1.480 | -0.010 | -0.7% | $1.500 | $1.540 | $1.470 | 1,768,400 | |
| $1.490 | +0.010 | +0.7% | $1.450 | $1.550 | $1.450 | 1,226,100 | |
| $1.480 | -0.030 | -2.0% | $1.530 | $1.530 | $1.475 | 1,194,600 | |
| $1.510 | +0.020 | +1.3% | $1.470 | $1.540 | $1.445 | 1,192,700 | |
| $1.490 | -0.050 | -3.2% | $1.540 | $1.540 | $1.440 | 1,286,100 | |
| $1.540 | +0.010 | +0.7% | $1.530 | $1.580 | $1.500 | 1,467,300 | |
| $1.530 | -0.070 | -4.4% | $1.570 | $1.610 | $1.515 | 1,334,700 | |
| $1.600 | -0.045 | -2.7% | $1.660 | $1.710 | $1.560 | 1,434,500 | |
| $1.645 | -0.175 | -9.6% | $1.790 | $1.815 | $1.630 | 2,024,100 | |
| $1.820 | -0.070 | -3.7% | $1.880 | $1.880 | $1.720 | 1,989,000 | |
| $1.890 | -0.130 | -6.4% | $2.000 | $2.010 | $1.880 | 2,342,800 | |
| $2.020 | -0.340 | -14.4% | $2.380 | $2.380 | $1.890 | 2,957,900 | |
| $2.360 | +0.010 | +0.4% | $2.350 | $2.415 | $2.310 | 1,756,100 | |
| $2.350 | -0.030 | -1.3% | $2.420 | $2.431 | $2.350 | 522,500 | |
| $2.380 | +0.040 | +1.7% | $2.350 | $2.430 | $2.320 | 744,400 | |
| $2.340 | -0.010 | -0.4% | $2.330 | $2.370 | $2.270 | 937,100 | |
| $2.350 | -0.120 | -4.9% | $2.470 | $2.490 | $2.305 | 778,900 | |
| $2.470 | +0.070 | +2.9% | $2.410 | $2.485 | $2.390 | 639,900 | |
| $2.400 | -0.020 | -0.8% | $2.420 | $2.420 | $2.350 | 574,500 | |
| $2.420 | +0.010 | +0.4% | $2.420 | $2.450 | $2.380 | 920,500 | |
| $2.410 | +0.050 | +2.1% | $2.410 | $2.480 | $2.405 | 364,700 | |
| $2.360 | -0.080 | -3.3% | $2.440 | $2.470 | $2.310 | 906,000 | |
| $2.440 | -0.160 | -6.2% | $2.590 | $2.590 | $2.430 | 945,200 | |
| $2.600 | -0.020 | -0.8% | $2.610 | $2.640 | $2.550 | 657,900 | |
| $2.620 | -0.040 | -1.5% | $2.710 | $2.737 | $2.610 | 624,300 | |
| $2.660 | -0.090 | -3.3% | $2.710 | $2.735 | $2.615 | 433,600 | |
| $2.750 | -0.100 | -3.5% | $2.840 | $2.895 | $2.740 | 438,500 | |
| $2.850 | -0.010 | -0.3% | $2.810 | $2.880 | $2.770 | 559,100 | |
| $2.860 | +0.010 | +0.4% | $2.820 | $2.905 | $2.810 | 307,100 | |
| $2.850 | -0.040 | -1.4% | $2.900 | $2.940 | $2.820 | 421,900 | |
| $2.890 | +0.020 | +0.7% | $2.880 | $2.978 | $2.815 | 587,400 | |
| $2.870 | +0.070 | +2.5% | $2.790 | $2.900 | $2.755 | 826,600 | |
| $2.800 | -0.190 | -6.4% | $2.950 | $2.970 | $2.780 | 1,033,700 | |
| $2.990 | -0.140 | -4.5% | $3.120 | $3.130 | $2.960 | 893,400 | |
| $3.130 | -0.110 | -3.4% | $3.248 | $3.260 | $3.120 | 652,700 | |
| $3.240 | -0.320 | -9.0% | $3.500 | $3.540 | $3.220 | 1,180,200 | |
| $3.560 | +0.450 | +14.5% | $3.370 | $3.680 | $3.365 | 2,474,400 | |
| $3.110 | -0.130 | -4.0% | $3.220 | $3.225 | $3.090 | 457,100 | |
| $3.240 | +0.110 | +3.5% | $3.170 | $3.290 | $3.160 | 480,800 | |
| $3.130 | -0.260 | -7.7% | $3.340 | $3.360 | $3.090 | 556,900 |
Splits
1 split · NASDAQ:AVXL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation |
- Ticker
- BX Swiss:12X1
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BX Swiss
- Currency
- CHF
What changed lately
Latest news release · Nov 3, 2026
Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors
Latest earnings call · Feb 9, 2026
Anavex Life Sciences (NASDAQ:AVXL) Q1 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Proxy Contest (September 2026)
Proxy contest · 25 slides
Latest news
Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors
Nov 3, 2026
Closed $1.20 (+5.3%) on Nov 3, 2026
Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
Oct 20, 2026
Closed $1.36 (0.0%) on Oct 21, 2026
Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
Oct 15, 2026
Closed $1.31 (-11.5%) on Oct 16, 2026
PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
Sep 18, 2026
Closed $2.42 (+0.4%) on Sep 18, 2026
Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change
Sep 17, 2026
Closed $2.41 (+2.1%) on Sep 17, 2026
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees
Sep 14, 2026
Closed $2.60 (-0.8%) on Sep 14, 2026
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
Sep 10, 2026
Closed $2.66 (-3.3%) on Sep 10, 2026
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4: 00 PM ET
Sep 8, 2026
Closed $2.85 (-0.3%) on Sep 8, 2026
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
Sep 2, 2026
Closed $2.85 (-1.4%) on Sep 3, 2026
Anavex Life Sciences Corp. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 37 in the last 12 months · 244 in all · newest Nov 3, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Feb 9, 2026
- Decks
- 35 decks · latest September 2026
Where Anavex Life Sciences Corp. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AVXL · Home listing | NASDAQ | United States | USD |
| gettex:12X1 | gettex | Germany | EUR |
| LS Exchange:A1411S | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1411S | Lang & Schwarz | Germany | EUR |
| LSE:0HFR | LSE | United Kingdom | USD |
| Tradegate:12X1 | Tradegate | Germany | EUR |
| BOATS:AVXL | BOATS | United States | USD |
| BX Swiss:12X1 · This page | BX Swiss | Switzerland | CHF |
| Dusseldorf:12X1 | Dusseldorf | Germany | EUR |
| Frankfurt:12X1 | Frankfurt | Germany | EUR |
| Hamburg:12X1 | Hamburg | Germany | EUR |
| Munich:12X1 | Munich | Germany | EUR |
| Stuttgart:12X1 | Stuttgart | Germany | EUR |
Valuation
Price/book 0.5× against a median of 1.9×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$63.50M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.39
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp. · NASDAQ:AVXL | US$54.83M | −US$63.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 2.39 |
| Kazia Therapeutics Ltd · NASDAQ:KZIA | US$56.22M | US$10.31M | n/a | 371× | n/a | 1.8× | n/a | 0.0× | 2.31 |
| OKYO Pharma Limited · NASDAQ:OKYO | US$56.15M | US$35.56M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.02 |
| Gwo Xi Stem Cell Applied Technology Co., Ltd. · TPEX:6704 | US$55.78M | US$51.66M | n/a | 9.1× | n/a | 2.5× | −43.0% | 0.3× | n/a |
| Cognition Therapeutics, Inc. · NASDAQ:CGTX | US$55.37M | US$25.10M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 2.28 |
| EyeGene, Inc. · KRX:185490 | US$55.25M | US$26.51M | n/a | 8.0× | n/a | 1.5× | −391.5% | 0.0× | n/a |
| AB Science SA · EURONEXT:AB | US$55.19M | US$50.53M | n/a | 39.2× | n/a | n/a | −132.6% | n/a | n/a |
| Azora Therapeutics, Inc. · NASDAQ:AZR | US$55.00M | US$33.00M | n/a | n/a | n/a | n/a | n/a | n/a | 1.00 |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.90M | US$46.37M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Nordicus Partners Corp · OTC:NORD | US$54.44M | US$54.44M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.45 |
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Median of the others | US$55.22M | US$34.28M | 39.2× | 1.9× | −132.6% | 0.0× | 1.01 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.00 USD · Analysts' mean
- EPS, year to Sep 2026
- -0.33 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Terrie Kellmeyer | Director, President, and Chief Executive Officer |
| Daniel Klamer | Vice President of Business Development and Scientific Strategy |
| Wolfgang Liedtke | Senior Vice President, Global Head of Neurology |
| Sandra Boenisch | Principal Financial Officer |
Board
| Director | Role |
|---|---|
| Axel Paeger | Independent Director |
| Claus van der Velden | Independent Director |
| Peter Donhauser | Member of the Board of Directors |
| Terrie Kellmeyer | Director, President, and Chief Executive Officer |
Events
- Next results
- Nov 24, 2026 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Anavex Life Sciences (NASDAQ:AVXL) Q1 2026 Earnings Call | Mon, Feb 09, 2026 · 8:30 AM ET | Replay |
| Anavex Life Sciences (NASDAQ:AVXL) Q4 2025 Earnings Call | Tue, Nov 25, 2025 · 8:30 AM ET | Replay |
| Anavex Life Sciences (NASDAQ:AVXL) Q3 2025 Earnings Call | Tue, Aug 12, 2025 · 8:30 AM ET | Replay |
| Anavex Life Sciences (NASDAQ:AVXL) Q2 2025 Earnings Call | Tue, May 13, 2025 · 8:30 AM ET | Replay |
| Anavex Life Sciences (NASDAQ:AVXL) Q1 2025 Earnings Call | Wed, Feb 12, 2025 · 8:30 AM ET | Replay |
| Anavex Life Sciences (NASDAQ:AVXL) Q4 2024 Earnings Call | Mon, Dec 23, 2024 · 8:30 AM ET | Replay |
| Anavex Life Sciences (NASDAQ:AVXL) Q3 2024 Earnings Call | Tue, Aug 06, 2024 · 8:30 AM ET | Replay |
| Anavex Life Sciences (NASDAQ:AVXL) Q2 2024 Earnings Call | Thu, May 09, 2024 · 8:30 AM ET | Replay |
| Anavex Life Sciences (NASDAQ:AVXL) Q1 2024 Earnings Call | Wed, Feb 07, 2024 · 8:30 AM ET | Replay |
| Anavex Life Sciences (NASDAQ:AVXL) Q4 2023 Earnings Call | Mon, Nov 27, 2023 · 8:30 AM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Aug 25, 2026 · Before open | +14.5% |
| Q2 2026 | Jun 30, 2026 | −0.8% |
| Q1 2026 | Feb 9, 2026 · Before open | +6.1% |
| Q4 2025 | Nov 25, 2025 | +25.3% |
| Q3 2025 | Aug 12, 2025 · Before open | −5.0% |
| Q2 2025 | May 13, 2025 · Before open | −5.0% |
| Q1 2025 | Feb 12, 2025 · Before open | +5.0% |
| Q4 2024 | Nov 25, 2024 · Before open | +0.2% |
| Q3 2024 | Aug 6, 2024 · Before open | +5.7% |
| Q2 2024 | May 9, 2024 · Before open | +4.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Feb 7, 2024 · Before open | −3.5% |
| Q4 2023 | Nov 27, 2023 · Before open | −10.0% |
| Q3 2023 | Aug 8, 2023 · Before open | +4.6% |
| Q2 2023 | May 9, 2023 · After close | +3.2% |
| Q1 2023 | Feb 7, 2023 · Before open | +5.8% |
| Q4 2022 | Nov 28, 2022 · Before open | −23.5% |
| Q3 2022 | Aug 9, 2022 · Before open | −5.7% |
| Q2 2022 | May 10, 2022 · Before open | +1.3% |
| Q1 2022 | Feb 9, 2022 · Before open | +5.8% |
| Q4 2021 | Nov 24, 2021 · Before open | +5.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Proxy Contest (September 2026) | Proxy contest | 25 slides | September 2026 |
| AD/PD 2026, Copenhagen | Conference | 27 slides | Mar 21, 2026 |
| Investor Presentation (February 2026) | Investor deck | 37 slides | February 2026 |
| Investor Presentation (January 2026) | Investor deck | 37 slides | January 2026 |
| Technical Presentation (February 2022) | Technical | 24 slides | Feb 2, 2022 |
| Investor Presentation (September 2021) | Investor deck | 43 slides | Sep 13, 2021 |
| Investor Presentation (August 2021) | Investor deck | 43 slides | August 2021 |
| Investor Presentation (July 2021) | Investor deck | 43 slides | July 2021 |
| Investor Presentation (April 2021) | Investor deck | 37 slides | April 2021 |
| Investor Presentation (February 2021) | Investor deck | 30 slides | February 2021 |
All 35 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2021) | Investor deck | 31 slides | January 2021 |
| CTAD 2020 | Conference | 33 slides | Nov 6, 2020 |
| Investor Presentation (November 2020) | Investor deck | 29 slides | November 2020 |
| Investor Presentation (June 2020) | Investor deck | 27 slides | June 2020 |
| Investor Presentation (February 2020) | Investor deck | 28 slides | February 2020 |
| CTAD 2019 | Conference | 17 slides | December 2019 |
| Investor Presentation (October 2019) | Investor deck | 38 slides | October 2019 |
| Investor Presentation (April 2019) | Investor deck | 29 slides | April 2019 |
| Investor Presentation (March 2019) | Investor deck | 29 slides | March 2019 |
| CTAD 2018 | Conference | 28 slides | October 2018 |
| Investor Presentation (May 2018) | Investor deck | 61 slides | May 2018 |
| Investor Presentation (March 2018) | Investor deck | 57 slides | March 2018 |
| Investor Presentation (June 2017) | Investor deck | 51 slides | June 2017 |
| Investor Presentation (2016) | Investor deck | 33 slides | Jun 15, 2016 |
| 2016 Rett Syndrome Symposium | Conference | 30 slides | June 2016 |
| Investor Presentation (2016) | Investor deck | 38 slides | Mar 27, 2016 |
| Conference Presentation (March 2016) | Conference | 27 slides | Mar 12, 2016 |
| 2016 Epilepsy Pipeline Conference | Conference | 19 slides | Feb 26, 2016 |
| CTAD 2015 | Conference | 18 slides | Nov 7, 2015 |
| Investor Presentation (2015) | Investor deck | 32 slides | Nov 6, 2015 |
| Investor Presentation (May 2015) | Investor deck | 34 slides | May 2015 |
| Investor Presentation (January 2015) | Investor deck | 29 slides | Jan 6, 2015 |
| Investor Presentation (2014) | Investor deck | 27 slides | Jul 13, 2014 |
| Investor Presentation (November 2013) | Investor deck | 14 slides | Nov 12, 2013 |
| BIO CEO Conference 2012 | Conference | 25 slides | Feb 14, 2012 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 37.6M | 41.8M | 43.7M | 37.9M | 33.0M | 25.2M | 22.3M | 13.3M | 10.7M | 7.25M |
| Selling, general and administrative | 13.8M | 11.0M | 12.0M | |||||||
| Operating income | -51.4M | -52.9M | -55.8M | -51.0M | -42.0M | -31.1M | ||||
| Depreciation and amortization | 1.25K | |||||||||
| Income before tax | -46.4M | -43.0M | -47.5M | -47.6M | -37.6M | -26.3M | -26.2M | -17.2M | -13.4M | -14.7M |
| Net income | -46.4M | -43.0M | -47.5M | -48.0M | -37.9M | -26.3M | -26.3M | -17.3M | -13.5M | -14.7M |
| Earnings per share, basic | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 |
| Earnings per share, diluted | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 102.6M | 132.2M | 151.0M | 149.2M | 152.1M | 29.2M | 22.2M | 22.9M | 27.4M | 9.19M |
| Current assets | 25.3M | 26.1M | 27.8M | 9.45M | ||||||
| Total assets | 103.8M | 135.6M | 154.4M | 152.7M | 161.6M | 34.5M | 25.3M | 26.2M | 27.8M | 9.50M |
| Accounts payable | 4.25M | 9.63M | 4.32M | 3.83M | 4.74M | 3.99M | 3.52M | 2.96M | ||
| Current liabilities | 10.8M | 7.31M | 5.04M | 3.88M | 3.58M | 3.19M | ||||
| Total liabilities | 8.95M | 15.3M | 12.5M | 10.2M | 10.8M | 7.31M | 5.04M | 3.58M | 3.19M | |
| Shareholders' equity | 94.9M | 120.3M | 141.9M | 142.5M | 150.8M | 27.2M | 20.3M | 22.3M | 25.9M | 6.31M |
| Shares outstanding | 86.7M | 84.8M | 82.1M | 77.9M | 75.9M | 62.0M | 52.7M | 45.9M | 43.3M | 36.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -39.0M | -30.8M | -27.8M | -24.2M | -30.4M | -21.3M | -18.5M | -12.6M | -9.02M | -9.24M |
| Cash from financing | 9.43M | 12.0M | 29.7M | 21.3M | 153.2M | 28.4M | 17.8M | 8.07M | 27.3M | 3.13M |
| Change in cash | -29.6M | -18.8M | 1.87M | -2.95M | 122.9M | 7.06M | -745.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 3, 2026 | Management or board change | SEC |
| 8-K · Current report | Nov 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 5, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 28, 2026 | Meeting outcome | SEC |
| DFAN14A | Sep 18, 2026 | Other filings | SEC |
| DFAN14A | Sep 18, 2026 | Other filings | SEC |
| DFAN14A | Sep 17, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Sep 15, 2026 | Meeting notice | SEC |
| DFAN14A | Sep 15, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Sep 14, 2026 | Meeting notice | SEC |
| DFAN14A | Sep 10, 2026 | Other filings | SEC |
| DFAN14A | Sep 9, 2026 | Other filings | SEC |
| DFAN14A | Sep 9, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Sep 8, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Sep 4, 2026 | Meeting notice | SEC |
| DFAN14A | Sep 3, 2026 | Other filings | SEC |
| DFAN14A | Sep 2, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 2, 2026 | Current report | SEC |
| DFAN14A | Sep 2, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Sep 1, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Aug 31, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 28, 2026 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 28, 2026 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Aug 28, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Aug 28, 2026 | Annual report | SEC |
| DEFC14A | Aug 27, 2026 | Other filings | SEC |
| PRRN14A | Aug 26, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 25, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Aug 24, 2026 | Meeting notice | SEC |
| DFAN14A | Aug 19, 2026 | Other filings | SEC |
| PRRN14A | Aug 17, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Aug 17, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Aug 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 17, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Aug 11, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 11, 2026 | Current report | SEC |
| DEFC14A | Aug 11, 2026 | Other filings | SEC |
| NT 10-Q · Late filing notice | Aug 10, 2026 | Explanation request | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| PREC14A | Jul 31, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| PREC14A | Jul 24, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 20, 2026 | Current report | SEC |
| 8-K · Current report | Jun 26, 2026 | Current report | SEC |
| 8-K · Current report | May 22, 2026 | Current report | SEC |
| 8-K · Current report | May 15, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | May 14, 2026 | Insider trade | SEC |
| NT 10-Q · Late filing notice | May 11, 2026 | Explanation request | SEC |
| 8-K · Current report | May 6, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | May 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 25, 2026 | Current report | SEC |
| 8-K · Current report | Feb 25, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Feb 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 9, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 10-K · Annual report | Nov 25, 2025 | Annual report | SEC |
| 8-K · Current report | Nov 25, 2025 | Results | SEC |
| 8-K · Current report | Nov 14, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 25, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 25, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 21, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 21, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 14, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 3, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 13, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 12, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 10-K · Annual report | Dec 23, 2024 | Annual report | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| S-3 · Registration statement | Jul 29, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 21, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | May 6, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 6, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 28, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 7, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 25, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2024 | Insider trade | SEC |
| 10-K · Annual report | Nov 27, 2023 | Annual report | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 30, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 28, 2023 | Other filings | SEC |
| 8-K · Current report | May 24, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Apr 14, 2023 | Current report | SEC |
| 4 · Change in ownership | Apr 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2023 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 4, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 4, 2023 | Meeting notice | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Feb 7, 2023 | Current report | SEC |
| 424B5 · Prospectus | Feb 7, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Feb 7, 2023 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 31, 2023 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Jan 27, 2023 | Annual report | SEC |
| 8-K · Current report | Dec 2, 2022 | Current report | SEC |
| 10-K · Annual report | Nov 28, 2022 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Aug 12, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 10, 2022 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 9, 2022 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Jul 29, 2022 | Other filings | SEC |
| 4 · Change in ownership | Jun 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2022 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 10, 2022 | Offer document | SEC |
| 4 · Change in ownership | May 27, 2022 | Insider trade | SEC |
| 8-K · Current report | May 27, 2022 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 10, 2022 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 11, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 11, 2022 | Meeting notice | SEC |
| 8-K · Current report | Apr 8, 2022 | Management or board change | SEC |
| 8-K · Current report | Mar 4, 2022 | Management or board change | SEC |
| SC 13G · Big-stake notice | Feb 9, 2022 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 9, 2022 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Feb 9, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2022 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 2, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Feb 2, 2022 | Current report | SEC |
| 10-K · Annual report | Nov 24, 2021 | Annual report | SEC |
| 8-K · Current report | Sep 27, 2021 | Current report | SEC |
| S-3ASR · Registration statement | Sep 24, 2021 | Offer document | SEC |
| 8-K · Current report | Sep 13, 2021 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2021 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2021 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2021 | Material contract | SEC |
| 424B5 · Prospectus | Jun 24, 2021 | Offer document | SEC |
| 3 · Initial statement of ownership | Jun 9, 2021 | Insider trade | SEC |
| 8-K · Current report | May 28, 2021 | Meeting outcome | SEC |
| 4 · Change in ownership | May 25, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2021 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Apr 12, 2021 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Apr 9, 2021 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Apr 1, 2021 | Meeting notice | SEC |
| 4 · Change in ownership | Feb 26, 2021 | Insider trade | SEC |
This page holds 200 of 638 filings. Open Filings
Cap table
Built by 6ix from Anavex Life Sciences Corp.’s releases · as of Aug 28, 2026
- Common shares
- 92,696,842
- Fully diluted
- 92,696,842
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 92,696,842 | Aug 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Aug 28, 2026 | 92,696,842 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| George F Tidmarsh Other companies: Revelation Biosciences, Inc. (Director · Jan 10, 2022 – Feb 11, 2025 · Past); La Jolla Pharmaceutical Co (President, CEO & Secretary, Director · Jan 19, 2012 – Apr 15, 2019 · Past); Spectrum Pharmaceuticals Inc (CSO and Head of R&D Operations · Jul 15, 2010 – Jan 3, 2011 · Past) | Executive Director, Director · Oct 10, 2011 – Feb 9, 2012 · Past |
| Cameron Durrant Other companies: Humanigen Inc (Chief Executive Officer, Director · Jan 7, 2016 – Jul 27, 2022 · Past); Immune Pharmaceuticals Inc (Director · Jul 10, 2014 – Jan 25, 2017 · Past) | Executive Chairman, Director · Dec 17, 2007 – Feb 3, 2011 · Past |
| Harvey Lalach Other companies: Fulucai Productions Ltd (CFO, Director · Jul 2, 2015 – Jul 2, 2015 · Past) | President COO Secretary, Director · Apr 25, 2006 – May 24, 2012 · Past |
| Sandra Boenisch Other companies: Destiny Media Technologies Inc. (Chief Financial Officer · Dec 13, 2017 – Oct 3, 2019 · Past) | Principal Financial Officer · Since at least Oct 1, 2015 |
| Alexandre Vamvakides | Chief Scientific Officer, Director · Jan 31, 2007 – Jan 31, 2007 · Past |
| Alison E Ayers | Director · May 20, 2008 – Jun 29, 2010 · Past |
| Angela Vernadaki | VP Business Development · Feb 7, 2007 – Feb 8, 2007 · Past |
| Athanasios Skarpelos | Director · Oct 1, 2013 – Mar 31, 2025 · Past |
| Axel Paeger | Independent Director · Since at least Feb 23, 2026 |
| Bernd Metzner | Director · May 7, 2014 – Sep 22, 2016 · Past |
All 22 people
| Person | Seat |
|---|---|
| Christopher U Missling | President and CEO, Director · Since at least Jul 5, 2013 |
| Claus van der Velden | Independent Director · Since at least Mar 2, 2018 |
| Daniel Klamer | Vice President of Business Development and Scientific Strategy · Since at least Nov 5, 2026 |
| Elliot Favus | Director · May 7, 2014 – May 21, 2021 · Past |
| Herve De Kergrohen | CEO · Jun 12, 2009 – Jun 12, 2009 · Past |
| Pei Ru Wu | COO, Director · Apr 25, 2006 – Apr 25, 2006 · Past |
| Peter Donhauser | Member of the Board of Directors · Since at least Feb 8, 2017 |
| Steffen Thomas | Director · Since at least Oct 1, 2018 |
| Terrie Kellmeyer | Director, President, and Chief Executive Officer · Since at least May 4, 2026 |
| William Sean Lowry | Director · Feb 24, 2011 – Feb 24, 2011 · Past |
| Wolfgang Liedtke | Senior Vice President, Global Head of Neurology · Since at least Jan 8, 2026 |
| Yang Wu | President & CEO, Director · Apr 25, 2006 – Apr 25, 2006 · Past |
Log in to ask 6ix AI your own questions about Anavex Life Sciences Corp.